Terms ending in 2038
Every in-force patent on Sandoz AG's record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,040,986 | Crystalline Forms of Cabotegravir Sodium In force · High confidence | Viiv Healthcare UK (No. 3) Limited | In force | High confidence | |
| US 11,037,047 | Improvements in counting devices In force · High confidence | Sandoz AG | In force | High confidence | |
| US 10,966,979 | Amorphous Solid Dispersion Of An Orally Available Gonadotropin-Releasing Hormone Receptor Antagonist In force · High confidence | Sandoz AG | In force | High confidence | |
| US 11,192,860 | Co-Crystal of an Orally Available Hif Prolyl Hydroxylase Inhibitor In force · High confidence | Sandoz AG | In force | High confidence | |
| US 11,851,666 | Multi-Copy Gene Protein Expression System In force · High confidence | Novartis Pharma AG | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Sandoz AG.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.